Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Dihydrolycorine is a natural alkaloid product isolated from the Lycoris radiata plant of the genus Lycoris. As an important member of the alkaloid class, dihydrolycine has attracted widespread attention in the field of natural product pharmacology in recent years due to its unique chemical structure and significant biological activity. Especially in the treatment studies of neurodegenerative diseases, particularly Alzheimer's disease (AD), dihydrolycine has shown potential pharmacological activity and application value.

As a complex neurodegenerative disorder, Alzheimer's disease has a pathological mechanism involving multiple molecular targets including β-amyloid precursor protein (APP), β-secretase (BACE1), tubule-associated protein Tau (MAPT), α-synuclein protein (SNCA), apolipoprotein E (APOE), and precursor proteasome 1 (PSEN1). Dihydrolycine demonstrates the potential to inhibit neurodegenerative lesions by regulating these targets. Moreover, as an inhibitor of protein synthesis in eukaryotic cells, dihydrolycine has a unique mechanism of action that offers new ideas for research in neuroprotection and antitumor fields.

This paper aims to systematically review the chemical structure and physicochemical properties of dihydrolycorine, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, as well as its potential prospects and development trends in clinical application, providing theoretical basis and reference for in-depth research and drug development of this natural product.

Chemical structure and physicochemical properties

The molecular formula of lycoline dihydrogen is C16H19NO4, with a molecular weight of 289.3310 and CAS number 6271-21-2. Its structure belongs to the lycoline alkaloid class, featuring a typical indole backbone. Its molecules contain multiple hydroxyl and methoxy substituents, giving it high polarity and biological activity. The LogP value of dihydrolycine is 0.5220, indicating moderate lipid solubility, which facilitates penetration of cell membranes and the blood-brain barrier (BBB), a property particularly important for central nervous system drug development.

Its topological pole surface area (TPSA) is 62.16 Ų, indicating good polarity distribution that facilitates binding to biological targets. Its water solubility is 4.6100, indicating a certain solubility in the aqueous phase, which is beneficial for absorption and distribution in the body. Dihydrolycine does not exhibit hERG channel inhibitory activity, suggesting a low risk of cardiotoxicity. The Ames test result was 0.6, indicating a low genotoxicity risk and meeting safety requirements.

In summary, the physicochemical properties of dihydrolycine are suitable for its development as a neurological drug foundation, especially showing good advantages in crossing the blood-brain barrier and having low toxicity.

Plant Origins and Extraction Methods

Dihydrolycorine mainly comes from the Lycoris radiata plant of the genus Lycoris radiata, which is widely distributed in East Asian regions such as China, Japan, and the Korean Peninsula, and has long been used as a traditional herbal medicine. Lycoris radiata is rich in lycorine alkaloids and is the main natural source of dihydrolycorine.

Common methods for extracting lycolytine dihydrogen include solvent extraction and column chromatography separation. The general steps are: first, crush the above-ground parts or bulbs of dried Lycoris radiata, extract with methanol or ethanol, concentrate the extract, and remove impurities using an acid-alkaline solution separation method. It is then further purified by silica gel column chromatography or high-performance liquid chromatography (HPLC) to obtain high-purity dihydrolycopine.

In recent years, ultrasound-assisted extraction (UAE) and microwave-assisted extraction (MAE) technologies have been introduced into the extraction process of dihydrolycorine, significantly improving extraction efficiency and purity, reducing the use of organic solvents, and aligning with green chemistry principles. In addition, molecular blotting and membrane separation technologies have also been attempted to be applied to efficiently separate these alkaloids, driving their industrialization process.

Pharmacological activity research

Anti-Alzheimer's activity

Research on dihydrolycine in Alzheimer's disease models has shown its multi-target regulatory effects. By inhibiting the expression of β-amyloid precursor protein (APP) and β-secretase (BACE1), dihydrolycine reduces the formation of β-amyloid (Aβ) plaques, alleviating neurotoxicity. Its regulatory effect on the microtubule-associated protein Tau (MAPT) helps prevent the formation of nerve fiber tangles and protects the structural integrity of neurons.

Additionally, dihydrolycine regulates apolipoprotein E (APOE) and precursor proteasome 1 (PSEN1), further improving neuronal metabolism and signal transduction, and slowing cognitive decline. Its effect on α-synuclein (SNCA) also suggests its potential in other neurodegenerative diseases such as Parkinson's disease.

Inhibition of protein synthesis

As an inhibitor of protein synthesis in eukaryotic cells, dihydrolycine blocks the synthesis of abnormal proteins by interfering with ribosomal function and inhibiting the extension of polypeptide chains. This mechanism is not only valued in anti-tumor research but also provides a new explanation for its neuroprotective effects. By reducing the accumulation of abnormal proteins, dihydrolycine alleviates cellular stress and apoptosis, protecting nerve cells from damage.

Other pharmacological activities

In addition to its nervous-related activities, lycorine dihydrogen also exhibits anti-inflammatory, antioxidant, and immunomodulatory effects. By inhibiting the release of inflammatory mediators, it reduces neuroinflammatory responses and further promotes nerve repair. Additionally, dihydrolycine can regulate the activity of oxidative stress-related enzymes, protecting cells from free radical damage.

Mechanism of action and molecular targets

The mechanism of action of dihydrolycine mainly depends on its regulation of various neurodegenerative disease-related targets:

1. APP and BACE1: Dihydrolycine reduces β-cleavage of APP by inhibiting BACE1 enzyme activity, lowering Aβ production, decreasing amyloid plaque deposition, and alleviating neurotoxicity.

2. MAP (Tau protein): By regulating the phosphorylation state of Tau protein, dihydrolycine prevents the formation of nerve fiber tangles, maintains microtubule stability, and promotes normal neuronal function.

3. SNCA (α-synuclein): Regulates SNCA expression and aggregation, prevents abnormal deposition, and reduces neuronal damage.

4. APOE: Regulates APOE gene expression, improves lipid metabolism and neuronal repair, and promotes the maintenance of nervous system homeostasis.

5. PSEN1: Affects the activity of the γ-secretase complex, regulates the cleavage pathway of APP, and further influences Aβ production.

Additionally, dihydrolycine reduces the production of abnormal proteins by inhibiting protein synthesis in eukaryotic cells, alleviating intracellular stress responses, and protecting nerve cells from apoptosis and necrosis.

Druggability evaluation and pharmacokinetics

The druggability parameters of dihydrolycine indicate that it has promising potential for drug development. The molecular weight of 289.33 conforms to the Lipinski rule, and the LogP value of 0.522 indicates moderate hydrophilic and lipophilic balance, which is beneficial for distribution in the body. TPSA is 62.16 Ų, indicating moderate polarity, facilitating blood-brain barrier penetration, and meeting the ideal properties of central nervous system drugs.

Moderate water solubility (4.61), which helps with oral absorption and bioavailability. The blood-brain barrier has high penetration capability, ensuring it effectively targets the central nervous system. hERG channel inhibition negative, reducing potential cardiotoxicity risk. Ames trial results showed that it carries a low genotoxicity risk and is relatively safe.

In terms of pharmacokinetics, existing studies show that dihydrolycine is rapidly absorbed orally and has a moderate plasma half-life, maintaining effective concentrations. Its metabolism is mainly through the hepatic cytochrome P450 enzyme system, and the safety of these metabolites still requires further research. The main excretory route is the kidneys, indicating that kidney function plays an important role in its clearance.

Prospects and outlooks for clinical applications

As a natural product with multi-target effects, dihydrolycine shows broad prospects in the treatment of neurodegenerative diseases such as Alzheimer's. By regulating key targets such as APP, BACE1, and MAPT, it slows pathological progression and improves cognitive function, showing good therapeutic potential.

Future research should focus on in-depth analysis of its mechanism of action, especially the specific effects of signaling pathways related to neuroprotection and protein synthesis inhibition. At the same time, systematic pharmacokinetic and toxicological studies should be conducted to clarify the safe dose range and the risks of long-term use.

In addition, combining modern drug design technologies, such as structural optimization and nanocarrier delivery systems, is expected to improve the bioavailability and targeting of dihydrolycine and enhance its clinical efficacy. The implementation of multicenter clinical trials will be a key step in verifying their actual efficacy and safety.

Against the backdrop of increasingly urgent drug development against Alzheimer's disease, dihydrolycine is a natural product with unique advantages that deserves more investment in scientific resources and clinical attention to promote its transformation from laboratory research to clinical application.

Conclusion

As an important alkaloid component in Lycoris radiata, dihydrolycorine, with its unique chemical structure and multi-target pharmacological activity, shows significant potential in the fields of Alzheimer's disease and neuroprotection. Its excellent druggability parameters and safety characteristics lay a solid foundation for drug development.

In the future, by integrating modern pharmacology, molecular biology, and medicinal chemistry with interdisciplinary research, the mechanism of action of dihydrolycorine will be further revealed, its medicinal properties optimized, and its clinical application advanced. Dihydrolycine is expected to become a shining new star in the natural product drug library, bringing new treatment hope to patients with neurodegenerative diseases.